Clinical Trials for Cancer Treatment

Study Title:

A Phase 2a Randomized, Double-Blinded, Placebo- Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulation in Patients with Sickle Cell Disease

What is the purpose of the study? (in Layman's terms, please describe the study)

The objectives of this study are: To characterize the pharmacokinetics/pharmacodynamics (PK/PD) of rifaximin ER and DER in subjects with sickle cell disease (SCD). To assess the safety and tolerability of rifaximin ER and
DER

Upstate Institutional Review Board (IRB) Number:

1837774

Study/Protocol ID:

RBSC2161

Study Phase:

Phase 2a

Patient Age Group:

Adults

Principal Investigator:

Bernard J Poiesz, MD

Where will the study take place?

Cancer Center

ClinicalTrials.Gov ID:

NCT05098028

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Laine Abernathy
Phone: 315-464-6528
Email: [email protected]

Return to Previous Page || Search Again